Oxycodone
Viewing r1 — Apr 27, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Oxycodone — oxy, percs — is a semi-synthetic opioid of the morphinan class. It is derived from thebaine, the same opium alkaloid that gives rise to morphine and codeine. It activates opioid receptors throughout the brain and spinal cord,[1] suppressing pain signaling and triggering the reward pathways that produce euphoria.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
morphine, heroin, hydromorphone +5 moremorphine, heroin, hydromorphone, hydrocodone, fentanyl, methadone, codeine, tramadol show less
Synthesized in 1916 by Freund and Speyer from thebaine, oxycodone entered clinical use in Germany the following year.[3] The 1996 launch of OxyContin — aggressively marketed for chronic non-cancer pain — became a catalyst for the US opioid epidemic.[4] It remains one of the most widely prescribed opioids worldwide despite tighter prescribing guidelines and abuse-deterrent reformulations.
Subjective effects include profound pain suppression, euphoria, heavy sedation, anxiolysis, and a dissolution of emotional discomfort. The experience is a warm, blanketing calm — more euphorigenic than Morphine,[5] defined as much by what disappears as by what arrives. Nausea, constipation,[6] and respiratory depression are characteristic unwanted effects.
Oxycodone produces rapid physical dependence, and the gap between a therapeutic and a fatal dose is narrow.[7] Tolerance to euphoria builds faster than tolerance to respiratory suppression — increasing the dose to chase the effect raises the risk of stopped breathing, and nearly all oxycodone deaths involve other depressants.[8] Decades of clinical and pharmacological research make this one of the best-characterized opioids in medicine.
History[edit]
Discovery
Oxycodone was synthesized in 1916 from thebaine — a non-analgesic opium alkaloid — by Martin Freund and Edmund Speyer.[9] The goal was morphine-like pain suppression with less abuse liability, a goal only partially achieved.[9] It entered clinical use in Germany in 1917.[3]
Clinical adoption and the opioid crisis
Oxycodone reached the United States in the 1950s in combination products — Percodan (with aspirin) and Percocet (with acetaminophen).citation needed The 1996 launch of OxyContin, marketed aggressively for chronic non-cancer pain, transformed prescribing and became emblematic of the US opioid epidemic's first wave.[4] US opioid overdose deaths rose from about 4,000 in 1999 to over 47,000 in 2017.[10]
Reformulation and modern era
In 2010, OxyContin was reformulated with a crush-resistant matrix to deter tampering; surveillance confirmed it worked.[11] Canada withdrew the original formulation in 2012, replacing it with abuse-deterrent OxyNEO,[12] and the CDC updated prescribing guidelines in 2016[13] and 2022.[14] Research continues into pharmacogenomics,[15] oxycodone-naloxone combinations,[16] and a conjugate vaccine.[17]
The name "oxycodone" derives from its chemical relationship to codeine: "oxy-" from the 14-hydroxy group and "-codone" marking the C-6 ketone. Street names — oxy, OC, percs (for Percocet combinations) — reflect how thoroughly branded formulations shaped popular awareness of the drug.
Chemistry[edit]
Structural class
Oxycodone belongs to the morphinan chemical family — the same scaffold as morphine, codeine, and hydromorphone.[5] It is made semisynthetically from thebaine, a minor opium alkaloid. The structural changes from morphine reduce first-pass liver breakdown, giving oxycodone substantially higher oral bioavailability.
Molecular properties
Its molecular formula is C₁₈H₂₁NO₄ (molecular weight 315.36 g/mol).[3][18] Pharmaceutical preparations use the hydrochloride salt for better dissolution.[18] Oxycodone is active as the parent compound — pain suppression comes from oxycodone itself, not from conversion to a downstream metabolite.[19]
Pharmacology[edit]
Mechanism of action
Oxycodone activates µ-opioid receptors distributed throughout the brain and nervous system.[2] This quiets pain signaling — nerve cells become less excitable, suppressing the transmission of pain.[2] Multi-receptor screening confirmed this as oxycodone's dominant action, with no significant activity at other major receptor targets.[1]
Pharmacokinetics
Oral bioavailability is 60–87%[5] — much higher than morphine's 20–30%, because oxycodone survives liver breakdown better. Peak levels arrive in 1–1.5 hours (immediate-release) or 2–3 hours (extended-release).[5][3] The liver breaks it down primarily via CYP3A4 and secondarily via CYP2D6;[20] the half-life is 3–5 hours, and the kidneys handle most elimination.[5][21]
Tolerance
Oxycodone tolerance develops through a molecular mechanism distinct from Morphine.[22] This divergence means cross-tolerance between the two drugs is incomplete, even though they act on the same receptor.[22] Switching between opioids can produce unexpected effects in either direction.
Neuroscience[edit]
Where it acts
Oxycodone's euphoria originates in the brain's reward circuit. Opioid receptor activation releases dopamine toward the nucleus accumbens — the brain's core reward hub — producing the compulsive pull the drug is known for. Dopamine D3 receptors play a specific role: blocking them reduces drug-seeking in animal models.[23]
Pain relief operates separately. Opioid receptor activation in the brainstem engages descending pathways that suppress pain signals at the spinal cord.[2]
Why it matters
With repeated use, a protein called DeltaFosB accumulates in reward circuits and drives lasting changes in motivation.[24] Early use brings strong euphoria with mild rebound effect discomfort. With continued use, the euphoria fades while the rebound intensifies — the drive shifts from seeking pleasure to escaping withdrawal distress.
Subjective Effects[edit]
Oxycodone produces a warm, settling calm that moves through body and mind together. Physical discomfort recedes and emotional unease quiets alongside it — the experience is defined as much by what disappears as by what arrives. At moderate doses, awareness narrows to a quiet, contented drift.
Compared with morphine, oxycodone is more euphorigenic and more sedating, with less nausea and itching.[5] Relative to hydromorphone, it occupies a lower-potency position with longer duration and higher oral bioavailability — making it the more common oral opioid in non-medical use.
Effect Grid
At common oral doses (10–30 mg), the full opioid experience manifests: pronounced euphoria, deep physical relaxation, significant analgesia, and a pervasive sense of contentment and emotional insulation. Cognitive effects include thought deceleration, reduced motivation, and dreamy mentation. Social inhibition decreases; conversations feel effortless. Music appreciation is enhanced.
Physically, constipation becomes likely, miosis is pronounced, and pruritus may intensify. Nausea occurs in a significant minority. Sedation increases substantially — the "nod" (oscillation between drowsiness and wakefulness) may begin at the upper end of this range. Respiratory rate begins to decrease.
Functional capacity is significantly impaired. The experience typically commits the user for 4–6 hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Sedation · Body high · Bodily heaviness · Tactile euphoria · Sexual arousal suppression · Spontaneous body sensations · Nausea · Muscle relaxation · Physical fatigue · Appetite suppression · Excessive sweating · Dizziness · Dry mouth · Temperature dysregulation · Vomiting · Bodily dissociation
Tactile euphoria · Sexual arousal suppression · Spontaneous body sensations · Nausea · Muscle relaxation · Physical fatigue · Appetite suppression · Excessive sweating · Dizziness · Dry mouth · Vomiting · Bodily dissociation
Motivation suppression · Confusion · Thought disorganization
Anxiety · Dysphoria
Sociability enhancement · Ego inflation · Depersonalization · Derealization · Cognitive disconnection
Cognitive disconnection
Timeline
First perceptible effects emerge as a subtle warmth in the chest and mild mood shift. Onset timing is dose-dependent and influenced by stomach contents.
Warmth spreads through the body. Analgesia, anxiolysis, and emerging euphoria build steadily. Mild pruritus and nausea may appear.
Maximum euphoria, analgesia, and sedation. The characteristic opioid warmth and emotional insulation are at their strongest. Nodding may occur at higher doses.
Effects remain clearly present but intensity has plateaued below peak levels. Sedation and contentment persist. Constipation and miosis continue.
Gradual return toward baseline. Analgesia and mood effects diminish progressively. Residual drowsiness and mild cognitive slowing persist.
Subtle residual warmth, mild contentment, or slight drowsiness may persist. Constipation may continue well beyond subjective resolution.
⚠ Do not drive or operate heavy machinery for at least 6 hours after subjective effects resolve, as psychomotor impairment outlasts perceived sobriety.
Safety[edit]
- Acute toxicity
- Critical
- Chronic toxicity
- High
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- morphine · heroin · hydromorphone
Toxicity
Acute toxicity
Oxycodone has a narrow therapeutic index — the gap between an effective dose and a dangerous one is small, and respiratory depression can occur even within the therapeutic range in opioid-naive or medically vulnerable individuals.[7] Overdose causes slowed or stopped breathing, pinpoint pupils, unconsciousness, slow heart rate, and cold skin — death follows from respiratory failure.[21]
Nearly all oxycodone overdose deaths involve multiple substances. Analysis of over 1,000 postmortem cases found only 3.3% involved oxycodone alone.[8] Benzodiazepines, alcohol, and other depressants were present in the overwhelming majority.[8]
Chronic toxicity
Long-term use is associated with immune suppression, particularly in elderly people.[7] Chronic opioid exposure disrupts hormones — lowering testosterone in men and estrogen in women — contributing to fatigue, sexual dysfunction, and bone loss.citation needed
Neonatal effects
Use during pregnancy can cause neonatal opioid withdrawal — the newborn begins withdrawing within the first day of life.[25] Animal studies suggest long-term effects on brain development in offspring.[26]
Pharmacogenomic risk
People who break down CYP2D6 unusually quickly produce more of the potent metabolite oxymorphone and may experience amplified effects at standard doses.[15]
Psychological risks
Oxycodone is highly reinforcing, and repeated use drives lasting changes in the brain's reward circuitry.[24] Between 21–29% of chronic pain patients prescribed opioids misuse them; 8–12% develop addiction.[27] A subset of prescription opioid users go on to use heroin.[28]
Dysphoria, anxiety, and insomnia during withdrawal drive relapse. Psychological craving persists long after physical withdrawal resolves.
Tolerance & Dependence
Tolerance develops with repeated use — escalating doses are needed for the same effect.[5] Tolerance to sedation and nausea develops faster than tolerance to constipation, which persists throughout use.[6] Stopping abruptly after prolonged use brings anxiety, muscle aches, diarrhea, insomnia, sweating, and intense craving.[29][30]
Cross-tolerance exists with all µ-opioid agonists — morphine, hydromorphone, fentanyl, Heroin — though it is incomplete due to divergent cellular tolerance mechanisms.[22]
Drug interactions
The most dangerous combinations involve other central nervous system depressants, which stack with oxycodone's respiratory suppression.
Alcohol adds to respiratory and CNS depression and is among the most common co-intoxicants in oxycodone deaths.[8]
Benzodiazepines are the most frequently lethal combination. Controlled studies confirm augmented abuse-related effects and impaired coordination;[31] benzodiazepines were the most common co-intoxicant in oxycodone postmortem cases.[8]
Gabapentinoids (pregabalin, gabapentin) co-prescribed with opioids significantly raise the risk of opioid-related death.[32][33]
Serotonergic drugs (SSRIs, SNRIs, MAOIs) can trigger serotonin overload — causing overheating, seizures, and potentially death — when combined with oxycodone.[34][35] The risk is lower than with tramadol but not zero.
CYP3A4 inhibitors substantially raise oxycodone blood levels.[36] CYP3A4 inducers reduce levels and may cause treatment failure.[36][37]
Contraindications
Absolute contraindications
- Pre-existing respiratory depression — oxycodone further suppresses breathing drive
- Acute breathing difficulty or elevated carbon dioxide levels
- Known allergy to oxycodone or any formulation component
- Bowel obstruction — oxycodone slows gut motility, worsening the blockage[21]
Relative contraindications
- Concurrent MAOI use — risk of serotonin syndrome and enhanced CNS depression
- Concurrent CYP3A4 inhibitor use — substantially increases oxycodone exposure[36]
- Liver impairment — slowed metabolism prolongs drug effects
- Kidney impairment — reduced excretion of oxycodone and metabolites
- Pregnancy — risk of neonatal withdrawal syndrome[25]
- Elderly patients — reduced clearance and increased sensitivity[7]
- History of substance use disorder — high reinforcing properties increase relapse risk
Harm Reduction[edit]
Forms & Identification
Oxycodone circulates as pharmaceutical tablets (immediate-release and extended-release), capsules, and oral solutions. In unregulated markets, counterfeit tablets pressed with fentanyl or fentanyl analogs represent a potentially lethal risk. No visual inspection can tell a genuine pharmaceutical tablet from a counterfeit.
Fentanyl test strips are the single most important harm reduction tool for anyone using oxycodone from outside a pharmacy. Even one counterfeit pill can deliver a fatal fentanyl dose. Test every batch — ideally every pill — as a minimum standard.
Guidelines
- Test all non-pharmacy oxycodone with fentanyl test strips before use
- Start with the lowest effective dose, particularly after any period of abstinence — tolerance drops rapidly and a previously tolerated dose can be fatal
- Keep naloxone accessible and ensure companions know how to administer it
- Avoid crushing or tampering with extended-release formulations — this releases the full dose at once and can cause overdose
- Do not use alone — have someone present who can recognize and respond to overdose
- Space doses to allow full clearance; do not redose before the previous dose has peaked
- Eat beforehand — opioids on an empty stomach increase nausea and may accelerate absorption
Set & Setting
Oxycodone's sedating and respiratory-depressant effects make environment critical to safety. Use in the presence of a sober companion who can monitor breathing and respond to overdose. Avoid situations where falling asleep unmonitored is likely — respiratory depression during sleep is a primary mechanism of opioid death.
Keep naloxone physically present — not stored in another room or vehicle. Comfortable, familiar surroundings reduce the likelihood of anxiety-driven redosing.
Aftercare & integration. After opioid use, physical recovery centers on hydration, nutrition, and sleep — opioids suppress appetite and disrupt normal sleep architecture. Constipation may persist for days; adequate fiber and fluid intake help restore normal bowel function.
For people using oxycodone for pain management, honest assessment of whether the drug is still serving its therapeutic purpose is a recurring question worth revisiting with a trusted clinician. Escalating doses, use beyond prescribed amounts, or using to manage emotional rather than physical pain are signs that the relationship with the drug has shifted.
Recovery & Support
Oxycodone dependence is treatable. Medication-assisted treatment with buprenorphine or methadone is the most evidence-supported approach, reducing both withdrawal severity and relapse risk. Clonidine can manage acute withdrawal symptoms including anxiety, agitation, and sweating.[29]
Stopping abruptly after prolonged use produces withdrawal — not life-threatening but intensely uncomfortable, typically peaking 24–72 hours after the last dose and resolving over 7–10 days. Medical supervision during detoxification is strongly recommended. Long-term support through peer groups, counseling, or structured treatment addresses the psychological component of dependence that persists well beyond physical withdrawal.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow, shallow, or stopped breathing. Blue or gray lips, fingertips, or skin. Unresponsive to voice or sternal rub. Gurgling or snoring sounds while unconscious. Any of these signals require immediate action.
Immediate steps:
- 1. Call emergency services immediately
- 2. Administer naloxone if available (intranasal or intramuscular) — it reverses opioid overdose within minutes
- 3. Place the person in the recovery position (on their side) to prevent choking
- 4. If breathing has stopped and training allows, begin rescue breathing
- 5. Stay with the person — naloxone wears off in 30–120 minutes, and oxycodone's effects last longer; a second dose may be needed
- 6. Do NOT induce vomiting; do NOT leave the person alone
What to tell the dispatcher: The substance (oxycodone or suspected opioid), the amount if known, when it was taken, current symptoms, and whether naloxone has been given. Good Samaritan laws in many jurisdictions protect callers from drug-related prosecution.
Reversal agent: Naloxone is a complete opioid antagonist available over-the-counter in many jurisdictions as nasal spray (Narcan) or injectable.[21] It reverses oxycodone-induced respiratory depression, but its duration is shorter than oxycodone's — repeat dosing and medical monitoring are essential. Community naloxone programs in the US documented approximately 26,463 overdose reversals as of 2014.[38]
Legal Status[edit]
Oxycodone is controlled internationally under the 1961 United Nations Single Convention on Narcotic Drugs and requires a prescription in all major jurisdictions.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | High abuse potential with accepted medical use. No refills permitted; requires written or electronic prescription. Schedule II since 1970.[39] |
| United Kingdom | Class A drug; Schedule 2 Controlled Drug (CD2) | Misuse of Drugs Act 1971. Possession without prescription: up to 7 years imprisonment. Supply or production: up to life imprisonment.[40] |
| Canada | Schedule I (Controlled Drugs and Substances Act) | Original OxyContin withdrawn February 2012; replaced by abuse-deterrent OxyNEO. Prescription required.[40] |
| Australia | Schedule 8 (Controlled Drug) | Strict state-level prescribing regulations. Possession without authority is illegal.[40] |
| European Union | Varies by member state | Generally classified as a prescription-only narcotic under national equivalents of the UN Single Convention. Individual member states set prescribing and dispensing controls. |
Legal status varies by jurisdiction and changes over time. This is not legal advice.
references
- [1] ^abOlson KM, Duron DI, Womer D, Fell R, Streicher JM (2019) Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids — PLoS ONE doi:10.1371/journal.pone.0217371
- [2] ^abcdHerman TF, Cascella M, Muzio MR, et al. (2026) Mu Receptors (StatPearls/NCBI) — Pharmacology, Biochemistry and Behavior (via StatPearls) PMID:31855381
- [3] ^abcdKinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M (2019) Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone — Clinical Pharmacokinetics doi:10.1007/s40262-018-00731-3
- [4] ^abKolodny A, Courtwright DT, Hwang CS, et al. (2015) The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction — Annual Review of Public Health doi:10.1146/annurev-publhealth-031914-122957
- [5]
- [6] ^abDe Giorgio R, Zucco FM, Chiarioni G, et al. (2021) Management of Opioid-Induced Constipation and Bowel Dysfunction — Advances in Therapy doi:10.1007/s12325-021-01766-y